173 related articles for article (PubMed ID: 3114691)
1. Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma?
Pereira MC; Sobrinho LG; Afonso AM; Ferreira JM; Santos MA; Sousa MF
Obstet Gynecol; 1987 Sep; 70(3 Pt 1):305-8. PubMed ID: 3114691
[TBL] [Abstract][Full Text] [Related]
2. Reduced dopaminergic inhibition of thyrotropin release in hyperprolactinemic ovulatory women.
Larrea F; Escorza A; Valencia X; Méndez I; Schiavon R; Forsbach G
Rev Invest Clin; 1991; 43(4):293-8. PubMed ID: 1798861
[TBL] [Abstract][Full Text] [Related]
3. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
[TBL] [Abstract][Full Text] [Related]
5. [The value of functional tests in diagnosis of prolactinoma].
Klockenbusch W; Distler W; von Ditfurth M; Graf M; Jahn K
Geburtshilfe Frauenheilkd; 1990 May; 50(5):383-7. PubMed ID: 2115483
[TBL] [Abstract][Full Text] [Related]
6. TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome.
Valensi P; Combes ME; Perret G; Attali JR
J Endocrinol Invest; 1996 May; 19(5):293-7. PubMed ID: 8796337
[TBL] [Abstract][Full Text] [Related]
7. Prolactin dynamics and tumour size in the prediction of surgical outcome for prolactinoma.
Gordon D; Richards A; Bulloch R; Cohen HN; Semple CG; Beastall GH; Thomson JA; Teasdale G
Q J Med; 1985 Feb; 54(214):141-51. PubMed ID: 3920723
[TBL] [Abstract][Full Text] [Related]
8. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
9. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.
Sawers HA; Robb OJ; Walmsley D; Strachan FM; Shaw J; Bevan JS
Clin Endocrinol (Oxf); 1997 Mar; 46(3):321-6. PubMed ID: 9156042
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of thyrotropin releasing hormone test in 129 patients with suspected tumoral hyperprolactinemia.
Smircić-Duvnjak L; Vizner B; Korsić M; Sekso M; Berković M
Coll Antropol; 2002 Dec; 26(2):635-40. PubMed ID: 12528293
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
[TBL] [Abstract][Full Text] [Related]
12. Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia.
Ghigo E; Pogliano G; Campagnoli C; Bertagna A; Camanni F; Massara F
J Endocrinol Invest; 1984 Oct; 7(5):525-7. PubMed ID: 6439773
[TBL] [Abstract][Full Text] [Related]
13. Defective regulation of prolactin secretion after successful removal of prolactinomas.
Camanni F; Ghigo E; Ciccarelli E; Massara F; Campagnoli C; Molinatti G; Müller EE
J Clin Endocrinol Metab; 1983 Dec; 57(6):1270-6. PubMed ID: 6415087
[TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia in clinically asymptomatic, fertile men: report of two cases.
Colon JM; Ginsburg F; Schmidt CL; Weiss G
Obstet Gynecol; 1989 Sep; 74(3 Pt 2):510-3. PubMed ID: 2503796
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of thyrotropin-releasing-hormone stimulation in patients with pituitary tumor.
Cook DM; Greer MA; Paxton H
West J Med; 1987 Aug; 147(2):161-4. PubMed ID: 3116772
[TBL] [Abstract][Full Text] [Related]
16. The importance of macroprolactinemia in the differential diagnosis of hyperprolactinemic patients.
Bağdatoğlu C; Bağdatoğlu OT; Muslu N; Köseoğlu A; Dağtekin A; Polat G; Dolgun H; Karataş MA
Turk Neurosurg; 2008 Jul; 18(3):223-7. PubMed ID: 18814107
[TBL] [Abstract][Full Text] [Related]
17. [Different effects of tricyclic (clomipramine and amitriptyline) and tetracyclic (maprotiline) antidepressors on the release of thyroid stimulating hormone, prolactin and growth hormone to thyrostimulating releasing hormone in patients with psychoaffective disorders (author's transl)].
Schlienger JL; Kapfer MT; Singer L; Stephan F
Acta Psychiatr Belg; 1980; 80(5):584-99. PubMed ID: 6786002
[TBL] [Abstract][Full Text] [Related]
18. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R
Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297
[TBL] [Abstract][Full Text] [Related]
19. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia.
Knoepfelmacher M; Villares SM; Nicolau W; Germek OO; Lerário AC; Wajchenberg BL; Liberman B
Horm Metab Res; 1994 Oct; 26(10):481-5. PubMed ID: 7851873
[TBL] [Abstract][Full Text] [Related]
20. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
